Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:21:45.520Z.
Calculation as of: 2026-10-06T18:21:45.520Z.
Quote observation: 2026-10-06T18:16:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84f755396c9cc6b6c9535f897ba0f48fef5a33e79b5fb4c136097311f2feddf3
PE RATIO
N/A
Market Cap
$1.03M
PE Ratio
N/A
TTM Avg
173046.93
3Y Avg
281427.36
5Y Avg
281427.36
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IM Cannabis Corp. (IMCC) | $1.12M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.20M | N/A | 0.03 | 0.03 | 0.03 |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | N/A | 173046.93 | 281427.36 | 281427.36 |
| NewcelX Ltd. (NCEL)vs › | $1.34M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.35M | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $897911.00 | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.35M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
